Bausch Health Companies Inc.: Ocular Hypertension trials
The registry lists 11 Ocular Hypertension studies with Bausch Health Companies Inc. as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 2Phase 2 6Phase 3 4Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and IOP-Lowering Effects of WB007CompletedNCT04149899Phase 1/2Results posted
- Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptCompletedNCT03896633Phase 1/2Results posted
- Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHTCompletedNCT01895972Phase 3Results posted
- Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01749930Phase 3Results posted
- Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01749904Phase 3Results posted
- Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptCompletedNCT01722604Phase 3Results posted
- BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01707381Phase 2Results posted
- Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular HypertensionCompletedNCT01223378Phase 2Results posted
- A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.CompletedNCT00595101Phase 2Results posted
- Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for GlaucomaCompletedNCT00441883Phase 2Results posted
- A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular HypertensionWithdrawnNCT04140279Phase 4